Hepatocellular Cancer | AG0001H
Pilot phase II study of Sandostatin LAR® in patients with advanced hepatocellular carcinoma.
Schema
Summary
Advanced hepatocellular carcinoma is a disease with minimal effective treatment options available and a very poor prognosis. This study hopes to determine the feasibility of delivering a treatment that has produced encouraging results in another small randomised study. The study determines whether treating people with Sandostatin LAR® means that they live longer and feel better. The study will also tell us whether the treatment has any impact on tumour growth and to see if the effect of Sandostatin LAR® on tumour growth is different when the tumour has somatostatin receptors. These results will help to decide whether or not to continue investigating this treatment in larger randomised studies.
